Image Place holder

Bijal D. Shah, MD


Specialty: Hematology/Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Shah’s primary clinical interests are in non-Hodgkin lymphomas (particularly mantle cell lymphoma) and acute leukemias (particularly acute lymphoblastic leukemia). As an internist and pediatrician, Dr. Shah also has a special interest in adolescent and young adult malignant hematology.

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology
  • Pediatrics

Fellowship:

  • Moffitt Cancer Center - Hematology & Oncology

Residency:

  • Duke University - Internal Medicine & Pediatrics

Medical School:

  • University of South Florida - MD
Participating Trials

CLINICAL TRIAL 18615
A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression CheckMate 436: CHECKpoint pathway and nivolumab clinical Trail Evaluation
Condition:
Intervention: Adcetris (Brentuximab vedotin); BMS-936558 (Nivolumab); Brentuximab vedotin; Nivolumab; SGN-35 (Brentuximab vedotin)
Open

CLINICAL TRIAL 19080
A Phase II Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Condition:
Intervention: MLN0128; TAK-228 (MLN0128)
Open

CLINICAL TRIAL 18329
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
Condition:
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18744
A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Condition:
Intervention: MEDI-570
Open

CLINICAL TRIAL 18816
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition:
Intervention: Atezolizumab (Tecentriq); Axicabtagene Ciloleucel (KTE-C19); KTE-C19; Not Applicable; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 17865
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Condition:
Intervention: SL-401
Open

CLINICAL TRIAL 18289
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
Condition:
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19
Open

CLINICAL TRIAL 17682
A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Condition:
Intervention: CC-122; CC-223; CC-292; Rituxan (rituximab); rituximab
Open

CLINICAL TRIAL 19072
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Condition:
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18880
A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 19070
Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel or the Treatment of Subjects with Relapsed/Refractory Large B-Cell Lymphoma
Condition:
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18930
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Condition:
Intervention: AMG103 (Blinatumomab); Blinatumomab; CC-5013 (Lenalidomide); Lenalidomide (Revlimid)
Open

CLINICAL TRIAL 19150
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma with Previously Treated Diffuse Large B-Cell Lymphoma
Condition:
Intervention: Bendamustine; TGR-1202; Ublituximab
Open

CLINICAL TRIAL 19341
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Condition:
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; MESNA; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19323
Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 812)
Condition:
Intervention: Adcetris (Brentuximab vedotin); BMS-936558 (Nivolumab); Brentuximab vedotin; Nivolumab; SGN-35 (Brentuximab vedotin)
Open

CLINICAL TRIAL 18496
An Open Label Phase II Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition:
Intervention: Zarnestra (tipifarnib); tipifarnib
Open

CLINICAL TRIAL 19158
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Condition:
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18610
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Condition:
Intervention: Cytarabine (Cytosine Arabinoside); PTX-200; Triciribine Phosphate monohydrate (PTX-200)
Open

CLINICAL TRIAL 19392
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients with Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
Condition:
Intervention: BNZ-1
Open

CLINICAL TRIAL 19390
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Condition:
Intervention: E7777
Open

CLINICAL TRIAL 19404
A Phase 1/2 Open-Label Multicenter Study of CC-122 in Combination with R-CHOP-21 for Previously Untreated Poor-Risk (IPI>/= 3) Diffuse Large B-Cell Lymphoma
Condition:
Intervention: CC-122; G-CSF; R-CHOP-21; prednisone
Open

CLINICAL TRIAL 19321
Phase I/IIA Study of the Oral 5-Azacitidine in Combination with the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients with T-Cell Lymphoma
Condition:
Intervention: 5-azacitidine; FK228 (Romidepsin); Romidepsin; Vidaza (5-azacitidine); azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 18858
A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein
Condition:
Intervention: ALRN-6924
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, Reed D, Lewis M, Freyer DR, Shah B, Luger S, Hayes-Lattin B, Jaboin JJ, Coccia PF, DeAngelo DJ, Seibel N, Bleyer A. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. JAMA Oncol. 2018 May;4(5):725-734. Pubmedid: 29450465.
  • So W, Pandya S, Quilitz R, Shah B, Greene JN. Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab. Mediterr J Hematol Infect Dis. 2018 May;10(1):e2018029. Pubmedid: 29755706. Pmcid: PMC5937972.
  • Brown PA, Shah B. Emerging Treatment Options for Acute Lymphoblastic Leukemia: Focus on CAR T-Cell Therapy. J Natl Compr Canc Ne. 2018 May;16(5S):651-655. Pubmedid: 29784748.
  • Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, Fenske TS, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi PF, Hamadani M, Forman SJ, Hussaini M, de Lima M, Olteanu H, Shah B, Chavez JC, Al Malki M, Kumar A, Ganguly S. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Tr. 2018 Mar;24(3):486-493. Pubmedid: 29225164.
  • Shah B, Zhao X, Silva AS, Shain KH, Tao J. Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All. Trends Cancer. 2018 Mar;4(3):197-206. Pubmedid: 29506670.
  • Sandoval-Sus JD, Faramand R, Chavez J, Puri S, Parra P, Sokol L, Kharfan-Dabaja MA, Shah B, Ayala E. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. Leuk Lymphoma. 2018 Jul;1-8. Pubmedid: 29963932.
  • Siegel SE, Advani A, Seibel N, Muffly L, Stock W, Luger S, Freyer DR, Douer D, Johnson RH, DeAngelo DJ, Hayes-Lattin B, Lewis M, Jaboin JJ, Shah B, Coccia PF, Bleyer A. Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD versus pediatric-inspired regimens. Am J Hematol. 2018 Jul. Pubmedid: 30058716.
  • Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e35-e39. Pubmedid: 29126867.
  • Jiang H, Lwin T, Zhao X, Ren Y, Li G, Moscinski L, Shah B, Tao J. Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma. Brit J Haematol. 2018 Jan. Pubmedid: 29383700. Pmcid: PMC6066460.
  • Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer. 2018 Jan;124(1):136-144. Pubmedid: 28902390. Pmcid: PMC5735034.
  • Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018 Feb;391(10121):659-667. Pubmedid: 29241979.
  • Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N. NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Ne. 2017 Sep;15(9):1091-1102. Pubmedid: 28874594.
  • Sandoval-Sus J, Sotomayor EM, Shah BD. Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. Hematol Oncol Stem Cell Ther. 2017 Sep;10(3):99-115. Pubmedid: 28404221.
  • Zhang X, Rastogi P, Shah B, Zhang L. B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy. Oncotarget. 2017 Sep;8(39):66728-66741. Pubmedid: 29029550. Pmcid: PMC5630450.
  • Cabanillas F, Shah B. Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):783-796. Pubmedid: 29126866.
  • Reed DR, Oshrine B, Pratt C, Fridgen O, Elstner C, Wilson L, Soliman H, Lee MC, McLeod HL, Shah B, Donovan KA, Pabbathi S, Turney M, Binitie O, Healy C, Nieder M, Shaw PH, Galligan A, Letson GD, Stern M, Quinn GP, Davies S. Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat. J Adolesc Young Adult Oncol. 2017 Dec;6(4):503-511. Pubmedid: 28777007. Pmcid: PMC5725631.
  • Abuodeh Y, Ahmed K, Echevarria M, Naghavi A, Grass GD, Robinson TJ, Tomblyn M, Shah B, Chavez J, Bello C, El-Haddad G, Harrison L, Kim S. Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. Ther Adv Hematol. 2017 Apr;8(4):129-138. Pubmedid: 28491264. Pmcid: PMC5405899.
  • Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017 Apr;8:14920. Pubmedid: 28416797. Pmcid: PMC5399304.
  • Ruan J, Shah B, Martin P, Schuster SJ. Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas. Ann Oncol. 2016 Jul;27(7):1226-1234. Pubmedid: 27052651.
  • Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2016 Dec;22(12):2201-2207. Pubmedid: 27660169.
  • Chavez JC, Sandoval-Sus J, Horna P, Dalia S, Bello C, Chevernick P, Sotomayor EM, Sokol L, Shah B. Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S170-S174. Pubmedid: 27521314.
  • Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S53-S56. Pubmedid: 27521325.
  • Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Douer D, Frankfurt O, Greer JP, Johnson RA, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Rao AV, Shah B, Uy GL, Wang ES, Zelenetz AD, Gregory K, Smith C. Acute Lymphoblastic Leukemia, Version 2.2015. J Natl Compr Canc Ne. 2015 Oct;13(10):1240-1279. Pubmedid: 26483064.
  • Nishihori T, El-Asmar J, Shah B, Hussaini M, Komrokji R, List A, Anasetti C, Kharfan-Dabaja MA. Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature. Bone Marrow Transplant. 2015 Oct;50(10):1388-1392. Pubmedid: 26191951.
  • Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, Katz O, Coleman M, Leonard JP. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. N Engl J Med. 2015 Nov;373(19):1835-1844. Pubmedid: 26535512. Pmcid: PMC4710541.
  • Quinn GP, Block RG, Clayman ML, Kelvin J, Arvey SR, Lee JH, Reinecke J, Sehovic I, Jacobsen PB, Reed D, Gonzalez L, Vadaparampil ST, Laronga C, Lee MC, Pow-Sang J, Eggly S, Franklin A, Shah B, Fulp WJ, Hayes-Lattin B. If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients' medical records. J Oncol Pract. 2015 Mar;11(2):137-144. Pubmedid: 25549654. Pmcid: PMC4799849.
  • Roe C, Bennett J, Zhang L, Chavez J, Shah B, Sokol L, Komrokji R. Hemophagocytic Lymphohistiocytosis in Malignant Hematology: Uncommon but Should Not Be Forgotten?. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S147-S150. Pubmedid: 26297268.
  • Holdener SL, Harrington L, Nguyen J, Horna P, Sagatys E, Shah B, Zhang L. Therapy-related B lymphoblastic leukemia with t(4;11)(q21;q23)/AF4-MLL in a patient with mantle cell lymphoma after recent aggressive chemotherapy: a unique case report. Int J Clin Exp Pathol. 2014 Mar;7(4):1800-1804. Pubmedid: 24817983. Pmcid: PMC4014267.
  • Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014 Aug;93(8):1305-1312. Pubmedid: 24590536.
  • Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr;99(4):450-456. Pubmedid: 24584873.
  • Beltran BE, Quiñones P, Morales D, Alva JC, Miranda RN, Lu G, Shah BD, Sotomayor EM, Castillo JJ. Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature. Leuk Res. 2013 Sep;37(9):1116-1119. Pubmedid: 23790442. Pmcid: PMC4038155.
  • Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, Bradner JE, Dalton WS, Sotomayor E, Tao J. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest. 2013 Nov;123(11):4612-4626. Pubmedid: 24216476. Pmcid: PMC3809771.
  • Martin P, Shah B. Limited-stage mantle cell lymphoma: not so different from advanced-stage. Leuk Lymphoma. 2013 Feb;54(2):217-218. Pubmedid: 22988842.
  • Trimaldi J, Carballido EM, Bowers JW, Anguiano AL, Zhang ZJ, Shah BD, Bruno S, List AF, Moscinski LC, Grady T, Agosti SJ, Kang L, Zhang L. B-lymphoblastic leukemia/lymphoma associated with t(8;13)(p11;q12)/ ZMYM2 (ZNF198)-FGFR1 : rare case and review of the literature. Acta Haematol. 2013 Dec;130(3):127-134. Pubmedid: 23594707.
  • Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Res. 2012 Sep;72(17):4440-4448. Pubmedid: 22728650. Pmcid: PMC3990429.
  • Shah BD, Martin P, Sotomayor EM. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control. 2012 Jul;19(3):227-235. Pubmedid: 22710898. Pmcid: PMC4015063.
  • Shah BM, Kemp R, Clearfield M. Using statins to treat 'healthy' patients: are we there yet?. Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):103-105. Pubmedid: 19402795.
  • Martin MG, Whitlatch NL, Shah B, Arepally GM. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. Am J Hematol. 2007 Jul;82(7):679-681. Pubmedid: 17266059.
  • Hankin A, Freiman H, Copeland B, Travis N, Shah B. A Comparison of Parallel and Integrated Models for Implementation of Routine HIV Screening in a Large, Urban Emergency Department. Public Health Rep. 131 Suppl 1:90-95. Pubmedid: 26862234. Pmcid: PMC4720610.
  • Knapp KK, Shah B, Barnett MJ, Taylor TN, Miller L. Provider status and the need for additional qualified residency opportunities— response to Kudla. J Am Pharm Assoc (2003). 54(3):216-216. Pubmedid: 24728605.